We showed, for the first time, a tremendously improved progression free survival time for 26% of PARPi treated epithelial ovarian cancer patients (with one to four preceding chemotherapy lines) with high corrected variant allele frequencies (cVAF) of either a BRCA1 or a BRCA2 mutation. Here, BRCA2 is linked to ovarian carcinoma.